Lexaria Bioscience Corp. announced on December 19, 2024, that it has begun dosing in its Phase 1b, 12-week chronic study GLP-1-H24-4. This registered study is designed to investigate the safety, diabetes control, and weight loss benefits of Lexaria's proprietary DehydraTECH technology.
The study aims to determine whether DehydraTECH improves the safety and effectiveness of existing GLP-1 drugs. This marks a significant advancement in Lexaria's clinical program, moving into a longer-duration human trial.
Initiating dosing in this comprehensive study is a key operational milestone. It brings the company closer to generating robust data on the chronic administration of its DehydraTECH-enhanced GLP-1 formulations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.